NVS Novartis CEO - we've had an increase in deal-making in China, primarily to license innovations that are developed there to enable them t

NVS Novartis CEO - we've had an increase in deal-making in China, primarily to license innovations that are developed there to enable them to be launched globally - On licensing drugs being developed in China, notes will continue with an "asset by asset" strategy